The Food and Drug Administration has cleared Novavax to move forward ... The event is now judged to be ALS, a rare ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

Additionally, the failure of reldesemtiv, Cytokinetics’ ALS drug candidate, in a late-stage trial in the spring of 2023 ...

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company developing novel treatments for severe ...

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...

An event aimed at finding a cure for Lou Gehrig’s disease, also known as ALS, is set to happen in South Alabama this weekend.

Leal Therapeutics has secured yet another multi-million financing deal as the Worcester-based biotechnology startup has ...

“has demonstrated the greatest therapeutic benefit seen to date in an animal model” of ALS, the company says on its website.

The meeting will finalize the Phase 3 study design for PrimeC, their leading drug candidate for Amyotrophic Lateral Sclerosis (ALS), and discuss New Drug Application (NDA) readiness. PrimeC has shown ...